|
Orthologous residues
|
|
RAP80 (human): S205‑p, RAP80 (mouse): S205‑p, RAP80 (rat): S205‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody, western blotting
|
|
Disease tissue studied:
ataxia-telangiectasia, bone cancer, breast cancer, Seckel syndrome
|
|
Relevant cell lines - cell types - tissues:
293T (epithelial), GM05757 (fibroblast), GM05823 (fibroblast), GM18366 (fibroblast), HCC1937 (breast cell), MCF-7 (breast cell), U2OS (bone cell)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
ATR (human)
|
genetic knockout/knockin of upstream enzyme
|
|
|
KINASE
|
ATM (human)
|
genetic knockout/knockin of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
ionizing radiation
|
|
|
|
increase
|
|
|
|
ionizing radiation
|
BRCA1 (human)
|
|
no effect upon treatment-induced increase
|
|
|
UV
|
|
|
|
increase
|
|
|
